Stay updated with breaking news from Dave Happel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN MATEO, Calif., May 06, 2024 -- Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic...
SAN MATEO, Calif., March 25, 2024 -- Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional...
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis
Canvas Dx is indicated as an aid in the diagnosis of ASD in patients between the ages 18 months and 5 years old who are at risk of developmental delay.